STOCK TITAN

Alector, Inc. - $ALEC STOCK NEWS

Welcome to our dedicated page for Alector news (Ticker: $ALEC), a resource for investors and traders seeking the latest updates and insights on Alector stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alector's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alector's position in the market.

Rhea-AI Summary
Alector, Inc. (ALEC) reports successful enrollment in pivotal INFRONT-3 Phase 3 latozinemab clinical trial and completion of INVOKE-2 Phase 2 trial of AL002 for Alzheimer's disease. $588.9 million in cash provides runway through 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.3%
Tags
-
Rhea-AI Summary
Alector achieves target enrollment in Phase 3 clinical trial for latozinemab in frontotemporal dementia
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
-
Rhea-AI Summary
Alector completes enrollment in Phase 2 trial of AL002 for Alzheimer's disease, data expected in Q4 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.76%
Tags
Rhea-AI Summary
Alector, Inc. to participate in upcoming investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.54%
Tags
conferences
-
Rhea-AI Summary
Alector reported Q2 2023 financial results and provided business updates. Cash position is $630.0 million. Enrollment in INVOKE-2 trial of AL002 in Alzheimer's disease to be completed in Q3 2023. Enrollment in INFRONT-3 trial of latozinemab in FTD-GRN to be completed in Q4 2023. Revenue guidance for 2023 increased to $90-100 million. R&D expenses decreased to $210-220 million. Cash sufficient through 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.38%
Tags
-
Rhea-AI Summary
Alector, Inc. will host a conference call and webcast on August 3, 2023, to discuss second quarter results and provide a mid-year business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.2%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.27%
Tags
-
Rhea-AI Summary
Alector, Inc. will participate in a corporate presentation at the BofA Securities 2023 Healthcare Conference on May 10, 2023. A live webcast will be available on the Alector website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.34%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.36%
Tags
conferences
Alector, Inc.

Nasdaq:ALEC

ALEC Rankings

ALEC Stock Data

519.51M
75.76M
9.93%
79.61%
6.76%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
SOUTH SAN FRANCISCO

About ALEC

we are a biotech company based in san francisco dedicated to the discovery and development of novel therapies harnessing the power of immune system to treat neurodegenerative diseases such as alzheimer's disease.